Skip to content
value.today

BioIQ, Inc.

Total raised
$58 M
4 rounds on record
Latest round
$14 M
Jul 2019
First round on record
May 2015
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BioIQ, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2019$14 MNo. 4$10 to $50 million

BioIQ, Inc.: Raise no. 4, Jul 2019

Investors in this round

12 investors had bought by the notice of Nov 25, 2019: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Exchange of Series G to G 1 Preferred
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Justin Bellante · Executive Officer, Director
  • Pete Desai · Executive Officer
  • Andrew Midler · Director
  • Brandon Cady · Director
  • Mike Cotton · Director
  • Patrick Cua · Director
  • Paul McCreadie · Director
  • Todd Creech · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series H Financing ; Series G-1 Exchange”

Signed by Pete Desai, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 25, 2019. Read the notice at the SEC.

equity, optionsSEC
Mar 2018$27 MNo. 3$10 to $50 million

BioIQ, Inc.: Raise no. 3, Mar 2018

Investors in this round

7 investors had bought by the notice of Apr 10, 2018: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,460,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brent Peus · Executive Officer
  • Justin Bellante · Executive Officer, Director, Promoter
  • Andrew Midler · Director
  • Brandon Cady · Director
  • Mike Cotton · Director
  • Patrick Cua · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Stifel, Nicolaus & Company, Incorporated (CRD 793) · St. Louis, MissouriSold in CA, MI, TN

Remarks in the notice

  • On fees: “(plus expenses)”
  • On the amounts: “Series G Financing”

Signed by /s/ Brent Peus, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 10, 2018. Read the notice at the SEC.

equitySEC
Aug 2016$7 MNo. 2$2 to $10 million

BioIQ, Inc.: Raise no. 2, Aug 2016

Investors in this round

21 investors had bought by the notice of Dec 14, 2016: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $8 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brent Peus · Executive Officer
  • Justin Bellante · Executive Officer, Director, Promoter
  • Andrew Midler · Director
  • Brandon Cady · Director
  • Jeff Closs · Director
  • Kathleen Shanahan · Director
  • Patrick Cua · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series F Financing has concluded. The balance of Preferred Series F shares will be held in reserve.”

Signed by /s/ Brent Peus, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 14, 2016. Read the notice at the SEC.

equity, optionsSEC
May 2015$10 MNo. 1$10 to $50 million

BioIQ, Inc.: Raise no. 1, May 2015

Investors in this round

50 investors had bought by the notice of May 16, 2016: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brent Peus · Executive Officer
  • Justin Bellante · Executive Officer, Director, Promoter
  • Brandon Cady · Director
  • Jeff Closs · Director
  • Kathleen Shanahan · Director
  • Patrick Cua · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Working Capital”

Signed by Brent Peus, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 16, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BioIQ, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2019).

    SEC Form D · Nov 2019

  • The industry group it chose in its notices: Other.

    SEC Form D · Nov 2019

That is all the official record says: BioIQ, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of BioIQ, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 50 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioIQ, Inc.
NameRoleNamed in
Justin BellanteExecutive officerNov 2019
Pete DesaiExecutive officerNov 2019
Brent PeusExecutive officerApr 2018
Andrew MidlerDirectorNov 2019
Brandon CadyDirectorNov 2019
Justin BellanteDirectorNov 2019
Mike CottonDirectorNov 2019
Patrick CuaDirectorNov 2019
Paul McCreadieDirectorNov 2019
Todd CreechDirectorNov 2019
Jeff ClossDirectorDec 2016
Kathleen ShanahanDirectorDec 2016
Justin BellantePromoterApr 2018